On October 25, 2017 Amgen (NASDAQ:AMGN) reported financial results for the third quarter of 2017 (Press release, Amgen, OCT 25, 2017, View Source [SID1234521169]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key results include:

Total revenues decreased 1 percent versus the third quarter of 2016 to $5.8 billion.
GAAP earnings per share (EPS) increased 3 percent to $2.76.
GAAP operating income decreased 3 percent to $2.4 billion and GAAP operating margin decreased 1.1 percentage points to 44.7 percent.
GAAP EPS and operating income were impacted by non-cash charges associated with the Company’s decision to discontinue internal development of AMG 899, an oral CETP inhibitor.
Non-GAAP EPS increased 8 percent to $3.27 driven by higher operating margins.
Non-GAAP operating income increased 4 percent to $3.0 billion and non-GAAP operating margin increased 2.7 percentage points to 55.6 percent.
Hurricane recovery efforts are well underway at our Puerto Rico manufacturing facility with no expected impact on product supply; expected 2017 EPS impact of $0.15 to $0.18.
2017 GAAP EPS guidance revised to $10.96-$11.20 and non-GAAP EPS guidance increased to $12.50-$12.70; total revenues guidance revised to $22.7-$23.0 billion.
The Company generated $3.3 billion of free cash flow in the third quarter of 2017.